Gilead Sciences Inc GILD

What the company does

Gilead Sciences Inc is a large-cap company in the Healthcare sector (Drug Manufacturers - General), with a market value of $193.5B, based in the USA.

It employs about 17,000 people and has been listed since Jan 22, 1992.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients.

Cheap or expensive? priced in line with its group

The company is loss-making, so it has no P/E — we compare on price-to-sales instead.

Its price-to-sales (P/S) is 6.4 versus 5.3 for the median of the Healthcare sector in our universe (25 companies) — priced in line with its group.

Revenue is growing 10% versus the same quarter last year.

The average analyst price target is 160.19, 3% above the current price (their view, not ours).

The stock sits at 91% of its one-year range (0% = the low, 100% = the high).

The risks

• • The company is loss-making.
• • Net debt is 2.0× shareholders' equity — high leverage.
• • Quarterly report in 4 days (2026-10-29) — a day the stock can move a lot.

Strengths

• ✅ Generates free cash flow — profit becomes cash in the bank.
• ✅ Buys back its shares (1% fewer shares in a year).
• ✅ Most analysts rate it buy (22 vs 1).
• ✅ Pays a dividend (2.0% a year).

What changed this week

Over the past week the stock fell 0.1% (for comparison: S&P 500 -0.4%, sector ETF XLV +1.4%).

This week's news

• Gilead Sciences (GILD) Could Be 22% Overvalued Following Its Liver Meeting Update finance.yahoo.com · 2026-10-24
  What the article says

  Gilead Sciences (GILD) is back in focus after outlining new data it plans to showcase at The Liver Meeting 2026 on its liver disease drugs Livdelzi and Hepcludex, drawing fresh attention to the depth of its pipeline. Recent news has landed against a strong run in Gilead Sciences' shares, with the 90 day share price… source ↗

• The Lanier Law Firm Supports Attorney General Ken Paxton in Reaching $45 Million Settlement with Gilead in Unlawful Inducement Scheme finance.yahoo.com · 2026-10-23
  What the article says

  Litigation sought reimbursements for violations of state law in prescribing practices, charges to Medicaid program HOUSTON, October 23, 2026--(BUSINESS WIRE)--Building on decades of holding pharmaceutical companies responsible for dangerous products and unlawful business practices, The Lanier Law Firm played a pivotal… source ↗

• Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions? finance.yahoo.com · 2026-10-22
  What the article says

  Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on Astute Optics - US's Substack. In this article, we will summarize the bulls' thesis on GILD. Gilead Sciences, Inc.'s share was trading at $156.51 as of October 20th 2026. GILD's trailing and forward P/E were 17.84 and 15.55… source ↗

• Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD finance.yahoo.com · 2026-10-22
  What the article says

  -- Clinical Program Adds a Potentially Differentiated Oral Peptide IL-23 Receptor Inhibitor to Gilead's Inflammation Portfolio -- -- HCXT-2001 Has Potential as a Monotherapy or in Combination with Other Gilead Programs to Address Unmet Needs in Immune-Mediated Inflammatory Diseases -- FOSTER CITY, Calif., October 22,… source ↗

• Sector Update: Healthcare Stocks Gain Late Afternoon finance.yahoo.com · 2026-10-22
  What the article says

  Healthcare stocks rose late Thursday afternoon with the NYSE Healthcare Index adding 1.7% and the St PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in source ↗

• Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release finance.yahoo.com · 2026-10-22
  What the article says

  Gilead Sciences (GILD) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a… source ↗

What changed since last week

No material change: same valuation verdict, same risk flags, price moved less than 3%.